Serum Chemerin Predicts the Prognosis of Patients With Dilated Cardiomyopathy


  • Dan Chen Department of Cardiovascular Medicine, Shiyan Renmin Hospital, Hubei University of Medicine, Hubei, China
  • Juan Wang Department of Cardiovascular Medicine, Shiyan Renmin Hospital, Hubei University of Medicine, Hubei, China
  • Jianglin Fu Department of Cardiovascular Medicine, Shiyan Renmin Hospital, Hubei University of Medicine, Hubei, China



Background: Chemerin is a newly discovered adipokine, which has been reported to be associated with the presence of dilated cardiomyopathy (DCM). The present study aims to evaluate the prognostic value of serum chemerin in patients with DCM.

Methods: A total of 214 patients with DCM was recruited and divided into 4 groups, according to quartiles of chemerin levels. Kaplan–Meier analysis was conducted to compare the survival rates among patients with different levels of chemerin, using the log-rank test. Multivariate Cox regression analysis was performed to assess the association of serum chemerin levels and occurrence of major adverse cardiac events (MACEs), including cardiac mortality, stroke and myocardial infarction.

Results: The Kaplan-Meier survival analysis indicated that patients with higher concentration of chemerin had shorter event-free survivals for MACEs (P < .01). Cox regression analysis showed that chemerin was a significant predictor of MACEs (Quartile 3 versus Quartile 1: HR=1.79, 95% CI: 1.31-2.79; Quartile 4 versus Quartile 1: HR=2.87, 95% CI: 1.79-4.25) and all-cause death (Quartile 3 versus Quartile 1: HR=1.56, 95% CI: 1.20-2.42; Quartile 4 versus Quartile 1: HR=2.28, 95% CI: 1.52-3.96) after adjusting for potential risk factors.

Conclusion: Serum chemerin should be a potential prognostic indicator in patients with DCM.


Bozaoglu K, Bolton K, McMillan J, et al. 2007. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148(10):4687-94.

Fatima SS, Rehman R, Baig M, et al. 2014. New roles of the multidimensional adipokine: chemerin. Peptides 62:15-20.

Gu P, Jiang W, Lu B, et al. 2014. Chemerin is associated with inflammatory markers and metabolic syndrome phenotypes in hypertension patients. Clin Exp Hypertens 36(5):326-32.

Kim NH, Kang PM. 2010. Apoptosis in cardiovascular diseases: mechanism and clinical implications. Korean Circ J 40(7):299-305.

Leiherer A, Muendlein A, Kinz E, et al. 2016. High plasma chemerin is associated with renal dysfunction and predictive for cardiovascular events - Insights from phenotype and genotype characterization. Vascul Pharmacol 77:60-8.

Maron BJ, Towbin JA, Thiene G, et al. 2006. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113(14):1807-16.

McNamara DM, Starling RC, Cooper LT, et al. 2011. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. J Am Coll Cardiol 58(11):1112-8.

Menzel J, di Giuseppe R, Biemann R, et al. 2017. Association between chemerin, omentin-1 and risk of heart failure in the population-based EPIC-Potsdam study. Sci Rep 7(1):14171.

Richardson P, McKenna W, Bristow M, et al. 1996. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93(5):841-2.

Rodriguez-Penas D, Feijoo-Bandin S, Garcia-Rua V, et al. 2015. The Adipokine Chemerin Induces Apoptosis in Cardiomyocytes. Cell Physiol Biochem 37(1):176-92.

Wu T, Chen Y, Du Y, et al. 2008. Serum Exosomal MiR-92b-5p as a Potential Biomarker for Acute Heart Failure Caused by Dilated Cardiomyopathy. Cell Physiol Biochem 46(5):1939-50.

Xiaotao L, Xiaoxia Z, Yue X, et al. 2012. Serum chemerin levels are associated with the presence and extent of coronary artery disease. Coron Artery Dis 23(6):412-6.

Yan Q, Zhang Y, Hong J, et al. 2012. The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine 41(2):281-8.

Yu M, Liang W, Xie Y, et al. 2016. Circulating miR-185 might be a novel biomarker for clinical outcome in patients with dilated cardiomyopathy. Sci Rep 6:33580.

Zhang O, Ji Q, Lin Y, et al. 2015. Circulating chemerin levels elevated in dilated cardiomyopathy patients with overt heart failure. Clin Chim Acta 448:27-32.

Zhou X, Tao Y, Chen Y, et al. 2019. Serum Chemerin as a Novel Prognostic Indicator in Chronic Heart Failure. J Am Heart Assoc 8(15):e012091



How to Cite

Chen, D., Wang, J., & Fu, J. (2020). Serum Chemerin Predicts the Prognosis of Patients With Dilated Cardiomyopathy. The Heart Surgery Forum, 23(3), E276-E280.